Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection Source: ISSN=ISSN 1810-6838, ISBN=, page=190 Year: 2006
Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Adverse effects of treatment in HIV-associated tuberculosis patients in Iran Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts Year: 2011
Adverse events during treatment for latent tuberculosis infection Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Adverse events in patients with MDR TB, treated by three types of the chemotherapy regimens Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
The impact of bedaquiline and delamanid containing regimens on liver function in patients multi-infected with pulmonary DR-TB, HIV and viral hepatitis Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
Adverse reaction of TB treatment with 2nd line drugs in a tuberculosis TB dispensary Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004
Primary drug resistance of mycobacterium tuberculosis in HIV-positive patients Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA) Year: 2016
Adverse effects in patients receiving therapy for multi-drug resistant tuberculosis in Latvia Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003
Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018 Year: 2019
Adverse effects of chemotherapy in patients with multidrug-resistant tuberculosis with alcohol abuse and without one Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018
HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Anti tubercular chemoprophylaxis regimens in HIV seropositives with latent tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 566s Year: 2002
Bedaquiline in the treatment of patients with co-infection HIV/tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018
Anti-tuberculosis drug concentrations and treatment outcomes in patients with both tuberculosis and HIV infection Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001
Safety of the endobronchial valve use in the complex treatment of patients with destructive MDR/XDR TB associated with HIV infection. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019 Year: 2020